Business
CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization to Advance Regional Influenza Protection in the Region of the Americas
CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization to Advance Regional Influenza Protection in the Region of the
About this update from Csl Limited
BUENOS AIRES, ARGENTINA - CSL Seqirus announced that it has entered into a pioneering long-term agreement with PAHO Regional Revolving Fund to advance influenza protection in the LATAM region. Under this multi-year agreement, CSL Seqirus, a leading global influenza vaccine manufacturer, will supply its innovative, differentiated portfolio of influenza vaccines, working with long-term production partner Sinergium Biotech, a prominent Argentinean vaccine company, to localize vaccine filling and distribution. This strategic alliance combines CSL Seqirus's global leadership in influenza with Sinergium Biotech's industrial and regulatory capabilities at its plant in Garin , Buenos Aires Province . As part of a shared commitment to strengthening regional vaccine supply, CSL Seqirus and Sinergium Biotech will invest $10 million USD to enable the transfer of technology capability, adding to the recent $25 million USD investment by Sinergium Biotech to increase local filling capacity. This manufacturing alliance will strengthen capacity in the region, supporting a sustainable, reliable and scalable regional supply for PAHO Member States and laying a strong foundation for future pandemic preparedness. Dr. Lorna Meldrum , CSL Seqirus, VP Commercial Operations, International & Pandemic Response said the company is delighted to enter this important public health partnership with PAHO. 'Seasonal influenza continues to place a significant burden on families, communities and health systems across the Pan American Region . Through this landmark partnership we will bring together the strength of our differentiated influenza vaccine portfolio with PAHO's regional leadership and networks-supporting countries to strengthen prevention efforts today while building greater resilience for the future.' Gonzalo Pereira , CSL Seqirus General Manager, Commercial Operations LATAM, said providing access to proven innovative technology to help protect public health in the region was a priority. 'We are excited to bring our differentiated cell-based and adjuvanted vaccine technology to the region. Public health protection is delivered through strong partnerships, and we are proud to join with PAHO to help advance regional preparedness and most importantly reduce the devastating impacts of flu.' Impact of Influenza across the Region Influenza is one of the fastest-changing vaccine-preventable diseases and has a significant impact on people and health systems across PAHO member states. It can cause mild to severe illness, and at times, can lead to death. According to recent analyses made in six South American countries with a total population of 307 million people, PAHO estimates that the yearly influenza-associated burden of disease ranged between 51 and 78 million mild-to-moderate influenza illnesses (16 to 25% of the total population), between 323,379 and 490,049 hospitalizations, and between 22,662 and 46,971 deaths during the 2015-2019 influenza seasons, underscoring the ongoing impact of the disease on communities and healthcare services. PAHO's Technical Advisory Group on Vaccine-Preventable Diseases recommends all countries should establish a seasonal influenza vaccination policy aimed at protecting children aged 6-23 months, pregnant women, individuals with chronic illness, older adults, and health workers. Differentiated Vaccine Platforms Enhancing Influenza Protection Developing influenza vaccines across all age groups in expanded markets is a strategic priority for CSL Seqirus. This includes further advancing cell-based manufacturing technology and MF59 adjuvant to enhance the protection of those particularly vulnerable to influenza, such as children and older adults. Cell-based influenza vaccines are designed to be a better match to WHO-selected influenza strains and help improve vaccine effectiveness by eliminating changes that can occur in the traditional influenza vaccine manufacturing process. In large, real-world studies, cell-based influenza vaccines have demonstrated up to 19.8% greater vaccine effectiveness than traditional egg-based vaccines in preventing test-confirmed influenza. MF59 adjuvant technology is designed to create a strong, broad and durable immune response in older adults, whose immune systems may respond less effectively to standard vaccines. Its use supports efforts to reduce severe influenza outcomes and hospitalisations among people aged 65 and over. Cell-based influenza vaccine manufacturing is well suited to enabling pandemic preparedness as it reduces reliance on large volumes of critical materials and is a modern, efficient and highly scalable alternative to traditional manufacturing methods. About CSL Seqirus CSL Seqirus is part of CSL (ASX:CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S. , the U.K. and Australia , CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world. About Sinergium Biotech Sinergium Biotech is a leading Argentine pharmaceutical company, recognized as a reference in the development, production, and commercialization of highly complex vaccines and biotechnological medicines in the region. Committed to the highest international standards, Sinergium Biotech operates under Good Manufacturing Practices (GMP) and strictly complies with regulations set by the National Administration of Drugs , Food and Medical Technology (ANMAT), in line with Mercosur regulations. Forward-Looking Statements This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Contact: Melanie Kerin Tel: +44 7345 433260 Email: [email protected] (C) 2026 Electronic News Publishing, source ENP Newswire